Get started
ABBOTT LABORATORIESABBOTT LABORATORIESABBOTT LABORATORIES

ABBOTT LABORATORIES

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

ABT trade ideas

ABT Strong Bullish Momentum – Move Toward $127.00 ExpectedNYSE:ABT is exhibiting strong bullish momentum, supported by a significant breakout above prior consolidation levels. The alignment of moving averages and the strength of recent price action suggest further upside potential, with the next logical target at $127.00. The price has surged above key moving averages, including the 50 EMA, 100 EMA, and 200 EMA, all of which are trending upward. This confirms sustained momentum and further supports the bullish case.
NYSE:ABTLong
by THE-BUFFALO
ABT -CUP and HandleA little late posting this idea but I believe I identified a cup - and- handle pattern on the daily chart in ABT. I was able to enter the trade in the pull back of the 'handle' when volume was starting to dry up at $113.25. Prior to the formation of the pattern there was a ~29% run up on the stock. Playing this conservatively I am setting my price targets at 12% ($134.40) and 24% ($148.8) above the high of the pattern. Where I will sell half of my position at the first target and the second half at the second target. Initially my first Stop Loss is set just beneath the 'handle' at $106.99
NYSE:ABTLong
by Notbadchad
Abbott Laboratories | Chart & Forecast SummaryOn The 15 Minutes Chart You Can See # A Trend | A Time Frame Conductive - This Measurement on Session Means; * Support & Resistance | HH & HL's and also a * Trade Area | Focus & Motion Ahead Containing A Falling Wedge That Acts Like Support On The Valid Target Dotted Through The Arrow Confirmation The Unnumbered Retracement You Can See Here, Indicates A 50% Retracement What Makes This A Valid Direction To Set Up Further Alliance In, Upwards On Replay Mode That Means An Uptrend Structured, While Measuring The Trend | Behaviour & Entry Principle. Development Into The Relevant Retracement Area You can Motivate Like This Overall Conclusion | Like The Trade Plan Execution & Risk Management on Demand This Tells Us; "It Is A Buy For Now" Thank You For Watching. See You Next Time
NYSE:ABTLong
by TradePolitics
Abbott Labs Shakes Off Downtrend, Sets Sights on $142 milestoneIn December 2021, the stock price hit an all-time high near the 142 mark, after which it experienced a significant drop. Following this decline, the price found support around the 90 level and began to recover. Last week, the stock managed to break through the upper boundary of the descending parallel channel, setting the stage for additional upward momentum. An immediate resistance level is noted at the 122 level, and a substantial movement is expected if this level is surpassed.
NYSE:ABTLong
by NaranjCapital
ABT updateThis is a trade I did enter after my initial post, I was bullish on ABT turning around, and hoping for falling interest rates which did occur. My strategy here was to purchase a LEAP before this breakout. I will hold this and sell covered-calls against it after earnings next week, if we get a large move I will make out heavily. I might decide to keep my LEAP and exercise it in 2026 due to the value I was able to snipe. -My short term target is the dashed green -Medium term 115$ -Next years target > 125$
NYSE:ABTLong
by Apollo_21mil
ABT, technical BTD Abbott Laboratories (ABT) recently swept its monthly fair value gap and saw a significant price increase from $102 to $104 on Friday. Despite the jump, there was no specific news driving this above-average ATR daily movement. The stock has been holding above the $100 level, building a solid base, and the chart looks promising. With earnings due on July 18, it's worth monitoring, though no trade will be entered yet. Keep an eye on further developments as the earnings date approaches.
NYSE:ABTLong
by thinkCNE
Abbott Laboratories Shows Resilience with Strong Q1 Performance In the dynamic landscape of healthcare, Abbott Laboratories (NYSE: NYSE:ABT ) stands out with its robust first-quarter performance, showcasing resilience and adaptability amidst challenging conditions. Bolstered by a surge in medical device sales and buoyed by promising growth across multiple sectors, Abbott has exceeded expectations and raised its annual guidance, signaling confidence in its trajectory. Let's delve deeper into the factors driving Abbott's success and the implications for investors. 1. Medical Devices Lead the Charge: Abbott's ( NYSE:ABT ) first-quarter success story is largely attributed to the stellar performance of its Medical Devices segment, which witnessed a remarkable organic growth of 14.3%. The star performer within this segment was FreeStyle Libre, demonstrating a phenomenal 23.3% organic growth, underscoring the growing demand for innovative healthcare solutions. 2. Diversification Pays Off: Abbott's diversified portfolio, spanning Established Pharmaceuticals, Nutrition, and Diagnostics, was pivotal in driving overall growth. With double-digit organic growth in Established Pharmaceuticals and substantial gains in Nutrition and Diagnostics, Abbott has showcased its ability to capture opportunities across various healthcare segments. 3. Strategic Innovations: The approval of Abbott's Heart Valve Repair Device by the FDA marks a significant milestone, reinforcing the company's commitment to advancing medical technology. This breakthrough underscores Abbott's relentless pursuit of innovation to address critical healthcare needs, thereby positioning the company for sustained growth and market leadership. 4. Earnings Beat and Guidance Revision: Abbott's impressive adjusted diluted earnings per share of $0.98 not only surpassed analyst estimates but also instilled confidence in the company's financial performance. The upward revision of its fiscal year 2024 adjusted EPS guidance to $4.55-$4.70 reflects management's bullish outlook and underscores Abbott's strong growth prospects in the coming quarters. 5. Market Response and Outlook: Despite the premarket dip in NYSE:ABT shares, Abbott's robust performance and revised guidance signal a compelling investment opportunity. With a solid foundation, innovative pipeline, and optimistic outlook, Abbott is poised to navigate uncertainties and deliver sustainable value to shareholders in the long term.
NYSE:ABT
by DEXWireNews
ABT breakout!ABT just broke out of a downtrend while simultaneously battling a key resistance zone. It did so, while gaining positive momentum within a monthly TTM squeeze (and firing the Daily Squeeze). If it can hold above the newly formed support, it might be ready for a bullish run up to its previous all-time-high, which is coincidentally equidistant from the newly formed low. Before it can do that, it needs to fight through resistance within the "golden" fibonacci zone (up to $122). I'll wait for it to break free of this zone before I try to ride it up to the next level and/or the high!
NYSE:ABTLong
by ThetaGator
Abbott Laboratories (ABT) Navigating Earnings Abbott Laboratories ( NYSE:ABT ) recently reported earnings that slightly missed expectations at the midpoint, causing a 3.3% dip in NYSE:ABT stock to $110.21. However, a closer look at the results reveals a more nuanced story. Despite the earnings guidance falling short by three pennies at $4.60 per share for the year, the health care giant remains resilient, projecting a robust 8% to 10% organic sales growth. Investors should pay attention as NYSE:ABT stock forms a saucer base with a potential buy point at $115.83. Strong Growth in Medical Devices: One of the key drivers behind Abbott's solid performance was the outstanding growth in its medical devices segment. Sales in this category surged 15.4% organically to $4.44 billion. Notably, the diabetes division played a significant role, with revenues reaching $1.55 billion, marking a substantial 20.7% increase. The star performer in this space was Abbott's body-worn glucose monitor, FreeStyle Libre, which contributed $1.4 billion in sales, up by an impressive 23.8% on an organic basis. Electrophysiology Segment Shines: Another highlight for Abbott ( NYSE:ABT ) was the electrophysiology segment, where revenue grew 15.9% organically to nearly $2.2 billion. This growth is particularly noteworthy considering the challenges posed by a new technology called pulsed field ablation (PFA), which is emerging in the electrophysiology testing space. Analysts believe that Abbott's robust performance in this segment allays fears of losing market share to PFA, underscoring the company's adaptability and resilience. Rapid Diagnostics Faces Headwinds: While Abbott ( NYSE:ABT ) celebrated success in medical devices and electrophysiology, the rapid diagnostics segment faced headwinds. Excluding Covid tests, sales declined by 13.7% to $862 million. The decline was attributed to a later-than-expected flu season, with cases spiking in January. Despite this setback, core lab sales managed to climb 9.7% to $1.37 billion, showcasing the diversified portfolio and the ability to navigate challenges. Conclusion: Abbott Laboratories' ( NYSE:ABT ) recent earnings report might have initially disappointed investors, but a deeper analysis reveals a company that is strategically positioned for growth. With a saucer base forming and a potential buy point at $115.83, savvy investors may see this dip in NYSE:ABT stock as a buying opportunity. Abbott's ability to innovate in the medical devices space, navigate challenges in rapid diagnostics, and shine in electrophysiology suggests that the company is well-poised for sustained success in the dynamic healthcare industry.
NYSE:ABT
by DEXWireNews
ABT Abbott Laboratories Options Ahead of EarningsIf you haven`t sold the regional top on ABT: Nor reentered this fantastic dip: Then analyzing the options chain and the chart patterns of ABT Abbott Laboratories prior to the earnings report this week, I would consider purchasing the 115usd strike price at the money Calls with an expiration date of 2024-2-16, for a premium of approximately $2.26. The chart is overextended and the RSI overbought, but I think there is one more leg to go before a correction. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
NYSE:ABTLong
by TopgOptions
1